Skip to main content
Equibles
REPL logo

REPL · Replimune Group, Inc.

Track REPL — free

Use REPL with AI

Ask our own analyst here, or connect this data to the AI you already use.

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

or use your own AI

The free Equibles MCP server lets any client query SEC filings, earnings calls, KPIs, holdings and prices directly — read-only, OAuth-secured, cited to the filing.

Claude ChatGPT Gemini
Server URL
https://mcp.equibles.com/mcp
All connection guides →
$15.04 -0.25 (-1.64%) At close · Sep 4
Russell 2000 member Rebalance outlook locked
Going-concern doubt — cleared Aug 14, 2026

The latest filing states the doubt was alleviated.

“As described in the Company's Annual Report on Form 10-K for the year ended March 31, 2026, substantial doubt existed about the Company's ability to continue as a going concern. The conditions that raised substantial doubt have been subsequently alleviated, as the Company raised approximately $141.0 million in net proceeds from an equity offering in August 2026.”
View the 10-Q filed Aug 14, 2026
Market Cap
$1.42B
Shares
94.22M

REPL metrics

57 of 114 screener metrics currently available.

Open in screener

Market overview

2 metrics
Share price
$15.04
Market cap
$1.42B

Price action

19 metrics
Price change (1W)
-3.0%
Price change (30D)
+10.0%
Price change (3M)
+58.8%
Price change (6M)
+86.4%
Price change (YTD)
+54.7%
Price change (1Y)
+158.9%
Trailing year
Price change (5Y)
-54.3%
52-week high
$15.98
52-week low
$1.70
Change from 52-week high
-5.9%
Change from 52-week low
+784.7%
Annualized volatility
217.3%
Beta
2.4
RSI (14D)
56.6
Price vs SMA 50
+21.6%
Price vs SMA 200
+74.7%
Avg volume (3M)
4.57M
Relative volume
0.2
Average dollar volume
$50.26M

Company

3 metrics
Sector
Healthcare
Industry
Biotechnology
Shares outstanding
94.22M

Valuation

12 metrics
P / E (TTM)
—
Trailing earnings
PEG ratio
—
EV / revenue
—
EV / EBITDA
—
EV / EBIT
—
P / sales
—
P / book
13.4
reciprocal yield 7.5%
FCF yield
-19.8%
TTM · current market cap
Buyback yield
—
P / FCF
—
P / operating cash flow
—
Earnings yield
-21.0%

Historical valuation

8 metrics
P / E historical average (3Y)
—
P / E historical average (5Y)
—
EV / revenue historical average (3Y)
—
EV / revenue historical average (5Y)
—
EV / EBIT historical average (3Y)
—
EV / EBIT historical average (5Y)
—
EV / EBITDA historical average (3Y)
—
EV / EBITDA historical average (5Y)
—

Dividends & buybacks

7 metrics
Dividend yield
—
Trailing 12 months
Payout ratio
—
Shareholder yield
—
Dividend / share (TTM)
—
Dividend growth YoY
—
Dividend growth streak
—
Last ex-dividend
—

Earnings calendar

2 metrics
Next earnings
—
Last earnings
2026-08-14

Profitability

9 metrics
Gross margin
—
Operating margin
—
Trailing 12 months
Net margin
—
Gross profit (TTM)
—
Operating profit (TTM)
−$297.74M
Net income (TTM)
−$297.01M
Trailing 12 months
Diluted EPS (TTM)
$-3.15
FCF margin
—
Effective tax rate
—

Per share

11 metrics
Revenue per diluted share (TTM)
—
Gross profit per diluted share (TTM)
—
Operating profit per diluted share (TTM)
—
EBITDA per diluted share (TTM)
—
Net income per diluted share (TTM)
—
Operating cash flow per diluted share (TTM)
—
Free cash flow per diluted share (TTM)
—
Capital expenditures per diluted share (TTM)
—
R&D per diluted share (TTM)
—
Stock compensation per diluted share (TTM)
—
Book value per share
$5.01

Growth

11 metrics
Revenue growth YoY
—
Year over year
Net income growth YoY
—
Revenue (TTM)
—
Trailing 12 months
EPS growth YoY
—
Shares change YoY
+5.8%
Year over year · more shares
Revenue CAGR (3Y)
—
Revenue CAGR (5Y)
—
EPS CAGR (3Y)
—
EPS CAGR (5Y)
—
FCF CAGR (3Y)
—
FCF CAGR (5Y)
—

Quality

14 metrics
Return on equity
-281.1%
Return on assets
-117.7%
Debt / equity
0.8
Current ratio
5.2
EBITDA (TTM)
−$294.35M
Free cash flow (TTM)
−$280.55M
Quick ratio
5.2
Interest coverage
—
Net debt / EBITDA
—
Return on invested capital
—
Trailing 12 months
Net cash
$111.21M
Latest balance sheet
Cash & equivalents
$185.36M
Total assets
$252.45M
Total debt
$84.11M

Cash flow & spend

7 metrics
Operating cash flow (TTM)
−$279.06M
Capital expenditures (TTM)
$1.49M
R&D (TTM)
$212.62M
SG&A (TTM)
$85.13M
Stock compensation (TTM)
$31.18M
R&D / revenue
—
Stock compensation / revenue
—

Ownership (13F)

3 metrics
13F filers
204
13F filer change QoQ
+16
Institutional ownership
110.4%

Short interest

3 metrics
Short interest
26.4%
Latest settlement · 4.0 days to cover
Days to cover
4.0d
Short-squeeze score
78 / 100

Insider activity

2 metrics
Net insider buying (90D)
−$1.04M
Insider-sentiment score
21 / 100

Risk flags

1 metrics
Going concern
—
Key facts CIK 1737953 CUSIP 76029N106 13F (30d) 133 filings 133 filers Visit website Investor relations